Philip Scheinberg

Philip Scheinberg pioneered the use of eltrombopag and other thrombopoietin receptor agonists in aplastic anemia, demonstrating that these agents can produce trilineage hematopoietic responses in patients with refractory bone marrow failure. His clinical trials have established eltrombopag as a standard component of first-line immunosuppressive therapy for aplastic anemia, transforming treatment outcomes. He continues to investigate how hematopoietic growth factor stimulation affects clonal evolution and cancer risk in BMF patients.